Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Secondary and therapy-related acute myeloid leukaemia, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No regimen produces durable remissions in TP53-mutated AML.
Whether CPX-351 helps patients under 60 or those fit enough for transplant regardless of induction.
Predicting and preventing therapy-related leukaemia in cancer survivors with clonal haematopoiesis.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
OS 14.
OS 9.
Newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, adults
A milestone in how this cancer is treated.